Alan Omar Vázquez-Álvarez

Dr. Alan Omar Vázquez-Álvarez

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2017 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
LBLorena Michele Brennan-Bourdon
Lorena Michele Brennan-Bourdon
ARAna Rosa Rincón-Sánchez
Ana Rosa Rincón-Sánchez
MIMaría Cristina Islas-Carbajal
María Cristina Islas-Carbajal
SHSelene G Huerta-Olvera
Selene G Huerta-Olvera
The aim of this study was to detect and analyze Adverse Drug Reactions (ADRs) through Intensive Pharmacovigilance (IPV) in hospitalized pediatric patients to improve drug safety. A prospective 6-month cross-sectional study was performed in the pediatric service of a regional hospital in Mexico in order to assess hospitalized children from 1 day to 18 years old. The inclusion criteria were: both genders, all hospitalization causes, and at least one prescribed medication (indistinct drug group). Notifications were performed through medical visits, phone calls, or spontaneous reports. ADR suspicions were assessed with severity scales: Naranjo algorithm, Schumock & Thornton and Hartwig and Siegel. From a total of 1083 hospital admissions, 19 ADRs were recorded. The average age of patients in years was 7.2 (±5.9). The causality assessment in this study showed that most of the ADRs were probable (68.4%) and 4 certain (8.2%); causality was mainly attributed to antibiotics (AB) and an antiepileptic drug. We found a relationship of AB with ADRs (p < 0.05) with an increased risk at the third day of prescription (p < 0.05). The average severity was level 2 and 21% were classified as “preventable”. Lastly, an increase in hospital stay associated with ADRs (p < 0.05) and with concomitant medications (p < 0.05), was also found. The most severe ADRs were hemolysis and toxic epidermal necrolysis. IPV was an effective tool for ADR prevention, detection, and treatment in hospitalized patients. The intensive monitoring approach in pharmacovigilance amplifies ADR detection and this translates into the improvement of drug safety in children.

Verified
Journal Article
Open access
PDF file
LCLuis Fernando Chavez-Mendoza
Luis Fernando Chavez-Mendoza
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
BTBlanca Miriam Torres-Mendoza
Blanca Miriam Torres-Mendoza
WTWalter Ángel Trujillo-Rangel
Walter Ángel Trujillo-Rangel
Erandis Dheni Torres-SanchezErandis Dheni Torres-Sanchez
Erandis Dheni Torres-Sanchez
DLDaniela LC Delgado Lara
Daniela LC Delgado Lara
Currently, approximately 40% of patients with dementia develop some form of sleep disorder. Benzodiazepines are widely prescribed but pose the risk of tolerance and cognitive decline; however, Z-drugs may offer safer alternatives. Therefore, this systematic review aimed to analyze the effect of benzodiazepines and Z-drugs on sleep disorders in patients with dementia. Two authors conducted a systematic search in PubMed, Scopus, Web of Science, Espistemonikos, and ACCESSSS for studies published between 2019 and 2024 using the MeSH terms “dementia”, “sleep disorders”, and “pharmacotherapy”. Randomized clinical trials comparing benzodiazepines, Z-drugs, or innovative medications with placebo or other drugs were included. Sleep and cognitive outcomes were assessed using validated instruments; the ROB-2 tool evaluated the risk of bias. The protocol was registered in “PROSPERO”. Three randomized clinical trials involving a total of 192 patients were included in the review. Zopiclone increased the main duration of nighttime sleep by 81 min, Zolpidem reduced nighttime awakenings by 21 min, and Eszopiclone improved sleep quality, benefited the progression of sleep architecture, and reduced mental symptoms such as fear and anxiety. Z-drugs show superior efficacy and safety over benzodiazepines, improving sleep and cognitive symptoms in dementia. Personalized treatment and further research across dementia subtypes are needed to optimize long-term outcomes.

10 January 2021 in Pharmacy
Verified
Journal Article
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
LBLeopoldo Baiza-Durán
Leopoldo Baiza-Durán
MBMariana Barajas-Hernández
Mariana Barajas-Hernández
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
(1) Background: drugs provide a significant benefit for patients who require medical treatment; however, their use implies an intrinsic potential danger, with the possibility of causing unwanted effects. These effects are known as adverse drug reactions (ADRs). Post-marketing drug safety surveillance detects unknown risks that have not been identified in clinical trials, and it is necessary to monitor marketed medications under real-life practice. Due to the scarce information about fixed combination of ciprofloxacin 0.3%/dexamethasone 0.1% (SDO), we performed a drug safety surveillance study. (2) Methods: A prospective non-controlled drug safety surveillance study was conducted in Peruvian population. A total of 236 patients prescribed SDO were included derived from 12 sites. Patients’ standardized information was collected through two phone calls, including demographics, medical history, prescribing patterns of SDO, concomitant medication, and ADRs in detail. The ADRs were classified by causality and severity, followed by outcome measures to identify new risk. (3) Results: 236 patients prescribed with SDO participated in the study and 220 were included. A total of 82 ADRs/220 patients were reported after the use of SDO, presenting a ratio 0.37 ADR/patient. The most frequent ADR with SDO administration was eye irritation (30%). All ADRs were classified as non-serious, and 97.5% (n = 80) were classified as mild while 2.5% as moderate (n = 2). No cases under the severe category were identified. (4) Conclusion: No new risks were found in the population where this study was conducted.

29 August 2022 in BJPsych Advances
Verified
Journal Article
Closed access
PDF file
JOJavier Ortiz-Orendain
Javier Ortiz-Orendain
SCSergio A. Covarrubias-Castillo
Sergio A. Covarrubias-Castillo
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
SOSantiago Castiello-De Obeso
Santiago Castiello-De Obeso
GQGustavo E. Arias Quiñones
Gustavo E. Arias Quiñones
LCLuis Enrique Colunga-Lozano
Luis Enrique Colunga-Lozano

25 November 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
LBLeopoldo Baiza-Durán
Leopoldo Baiza-Durán
MBMariana Barajas-Hernández
Mariana Barajas-Hernández
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
(1) Background: drugs provide a significant benefit; however, their use implies an intrinsic potential danger, with the possibility to cause unwanted effects. These effects are known as adverse drug reactions (ADRs). Post-marketing drug safety surveillance detects unknown risks that have not been identified in clinical trials and it is necessary to monitor marketed medications under real-life practice. Due to the scarce information about fixed combination of ciprofloxacin 0.3% / dexamethasone 0.1% (SDO), we performed a drug safety surveillance study. (2) Methods: A prospective non-controlled drug safety surveillance study was conducted in Peruvian population. A total of 236 patients prescribed SDO were included derivates from 12 sites. Patients' standardized information was collected through two phone calls, including demographics, medical history, prescribing patterns of SDO, concomitant medication, and ADRs in detail. The ADRs were classified by causality and severity, followed by outcome measures to identify new risk. (3) Results: 236 patients prescribed with SDO participated in the study and 220 were included. A total of 82 ADRs/220 patients were reported after the use of SDO, presenting a ratio 0.37 ADR/patient. The most frequent ADR with SDO administration was eye irritation (30%). The totality of the ADR was classified as non-serious, and the 97.5% (n=80) was classified as mild and 2.5% as moderate (n=2). No cases under the severe category were identified. (4) Conclusion: No new risks were found in the population where this study was conducted.

4 February 2022 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
Homero Contreras-SalinasHomero Contreras-Salinas
Homero Contreras-Salinas
MBMariana Barajas-Hernández
Mariana Barajas-Hernández
LBLeopoldo Martín Baiza-Durán
Leopoldo Martín Baiza-Durán
AVAlan Omar Vázquez-Álvarez
Alan Omar Vázquez-Álvarez
MBManuel Alejandro Bautista-Castro
Manuel Alejandro Bautista-Castro
LRLourdes Yolotzin Rodríguez-Herrera
Lourdes Yolotzin Rodríguez-Herrera
Erratum for the article Active Pharmacovigilance in Peruvian Population: Surveillance of a Timolol/Brimonidine/Dorzolamide Ophthalmic Fixed Combination